share_log

Becton, Dickinson and (NYSE:BDX) Price Target Raised to $295.00 at Morgan Stanley

Becton, Dickinson and (NYSE:BDX) Price Target Raised to $295.00 at Morgan Stanley

貝克頓、迪金森及(紐約證交所代碼:BDX)目標價格在摩根士丹利上調至 295.00 美元
kopsource ·  2023/02/04 09:21

Becton, Dickinson and (NYSE:BDX – Get Rating) had its price objective increased by Morgan Stanley from $290.00 to $295.00 in a research note issued to investors on Friday morning, Benzinga reports. The brokerage currently has an overweight rating on the medical instruments supplier's stock.

據Benzinga報道,在週五上午發佈給投資者的一份研究報告中,貝頓、迪金森和(紐約證券交易所代碼:BDX-GET評級)將摩根士丹利的目標價從290.00美元上調至295.00美元。該經紀公司目前對這家醫療器械供應商的股票評級為增持。

Several other equities analysts also recently weighed in on the stock. William Blair reissued an outperform rating on shares of Becton, Dickinson and in a research note on Friday, November 11th. Cowen reduced their price objective on Becton, Dickinson and to $255.00 in a research report on Wednesday, November 16th. Piper Sandler upped their target price on Becton, Dickinson and from $245.00 to $260.00 and gave the company a neutral rating in a report on Thursday. Evercore ISI reduced their price target on Becton, Dickinson and to $270.00 in a report on Wednesday, November 16th. Finally, Bank of America raised shares of Becton, Dickinson and from a neutral rating to a buy rating and upped their price objective for the company from $250.00 to $290.00 in a report on Tuesday, January 3rd. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of Moderate Buy and a consensus target price of $275.64.

其他幾位股票分析師最近也加入了該股的行列。威廉·布萊爾在11月11日星期五的一份研究報告中重新發布了對Becton,Dickinson和的股票的表現優於大盤的評級。考恩在11月16日(星期三)的一份研究報告中將他們對Becton和Dickinson的目標價格下調至255.00美元。派珀·桑德勒在週四的一份報告中將貝頓、迪金森和迪金森的目標價從245.00美元上調至260.00美元,並給予該公司中性評級。在11月16日週三的一份報告中,Evercore ISI將他們對Becton和Dickinson的目標價下調至270.00美元。最後,在1月3日週二的一份報告中,美國銀行將Becton和Dickinson的股票評級從中性上調至買入,並將該公司的目標價從250.00美元上調至290.00美元。三位分析師對該股的評級為持有,六位分析師對該公司股票的評級為買入。根據MarketBeat的數據,該公司目前的平均評級為中等買入,共識目標價為275.64美元。

Get
到達
Becton Dickinson and
貝頓·狄金森和
alerts:
警報:

Becton, Dickinson and Stock Down 1.1 %

Becton,Dickinson和股價下跌1.1%

BDX stock opened at $245.84 on Friday. The stock has a market capitalization of $69.88 billion, a P/E ratio of 46.38, a P/E/G ratio of 2.13 and a beta of 0.54. Becton, Dickinson and has a 52 week low of $215.90 and a 52 week high of $280.62. The firm has a 50-day simple moving average of $251.67 and a 200-day simple moving average of $244.48. The company has a quick ratio of 0.63, a current ratio of 1.07 and a debt-to-equity ratio of 0.56.

上週五,BDX股價開盤報245.84美元。該股市值為698.8億美元,市盈率為46.38,市盈率為2.13,貝塔係數為0.54。貝頓,迪金森,並有52周低點215.90美元和52周高點280.62美元。該公司的50日簡單移動均線切入位在251.67美元,200日簡單移動均線切入位在244.48美元。該公司的速動比率為0.63,流動比率為1.07,債務權益比率為0.56。

Becton, Dickinson and (NYSE:BDX – Get Rating) last released its earnings results on Thursday, February 2nd. The medical instruments supplier reported $2.98 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.30. Becton, Dickinson and had a return on equity of 13.52% and a net margin of 8.47%. The business had revenue of $4.59 billion for the quarter, compared to the consensus estimate of $4.59 billion. During the same quarter last year, the business posted $3.64 earnings per share. The business's quarterly revenue was down 2.8% compared to the same quarter last year. Equities analysts forecast that Becton, Dickinson and will post 12.2 earnings per share for the current fiscal year.
Becton,Dickinson和(NYSE:BDX-GET Rating)最近一次發佈收益結果是在2月2日星期四。這家醫療器械供應商公佈本季度每股收益為2.98美元,比普遍預期的2.68美元高出0.30美元。Becton、Dickinson和擁有13.52%的股本回報率和8.47%的淨利潤率。該業務本季度營收為45.9億美元,而市場普遍預期為45.9億美元。去年同一季度,該公司公佈的每股收益為3.64美元。與去年同期相比,該業務的季度收入下降了2.8%。股票分析師預測,Becton、Dickinson和本財年每股收益將達到12.2英鎊。

Becton, Dickinson and Dividend Announcement

貝頓、狄金森和股息公告

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 31st. Shareholders of record on Friday, March 10th will be paid a $0.91 dividend. The ex-dividend date is Thursday, March 9th. This represents a $3.64 annualized dividend and a dividend yield of 1.48%. Becton, Dickinson and's dividend payout ratio (DPR) is 68.68%.

該公司最近還宣佈了季度股息,將於3月31日(星期五)支付。3月10日(星期五)登記在冊的股東將獲得0.91美元的股息。除息日期為3月9日(星期四)。這意味着年化股息為3.64美元,股息收益率為1.48%。Becton,Dickinson and的股息支付率(DPR)為68.68%。

Institutional Inflows and Outflows

機構資金流入和流出

A number of hedge funds and other institutional investors have recently bought and sold shares of BDX. Red Tortoise LLC acquired a new position in Becton, Dickinson and during the 4th quarter worth approximately $25,000. Legend Financial Advisors Inc. lifted its holdings in Becton, Dickinson and by 105.6% during the 4th quarter. Legend Financial Advisors Inc. now owns 111 shares of the medical instruments supplier's stock worth $28,000 after buying an additional 57 shares during the last quarter. Trifecta Capital Advisors LLC acquired a new position in shares of Becton, Dickinson and during the 4th quarter worth about $31,000. Western Pacific Wealth Management LP purchased a new position in shares of Becton, Dickinson and in the 3rd quarter valued at about $30,000. Finally, Chilton Capital Management LLC purchased a new stake in Becton, Dickinson and during the second quarter worth approximately $39,000. 87.08% of the stock is currently owned by hedge funds and other institutional investors.

一些對衝基金和其他機構投資者最近買賣了BDX的股票。紅烏龜有限責任公司在迪金森的貝頓獲得了一個新的頭寸,並在第四季度獲得了大約2.5萬美元的價值。聯想金融顧問公司(Legend Financial Advisors Inc.)在第四季度增持了貝頓、迪金森的股份,增持幅度為105.6%。聯想金融顧問公司現在擁有111股這家醫療器械供應商的股票,價值28,000美元,在上個季度又購買了57股。Trifeta Capital Advisors LLC在第四季度收購了Becton,Dickinson的新股票,價值約3.1萬美元。西太平洋財富管理公司在第三季度購買了Becton,Dickinson的新股票頭寸,價值約30,000美元。最後,Chilton Capital Management LLC在第二季度購買了Becton,Dickinson的新股份,價值約3.9萬美元。87.08%的股票目前由對衝基金和其他機構投資者持有。

Becton, Dickinson and Company Profile

貝頓、狄金森和公司簡介

(Get Rating)

(獲取評級)

Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.

Becton,Dickinson&Co從事醫療用品、設備、實驗室設備和診斷產品的開發、製造和銷售。它通過以下部門開展業務:BD醫療、BD生命科學和BD Intervative。BD醫療部門生產醫療技術和設備,用於幫助改善醫療保健服務。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
  • MarketBeat Week in Review – 1/30 – 2/3
  • Are Penny Stocks Worth it? Should You Invest in Penny Stocks?
  • Zimmer Biomet Beats on Earnings, Growth May be Priced In
  • AI Software Maker EPAM Boasts Biggest Tech-Sector Rally
  • Ford Stock Going Forward After Big Earnings Flop
  • 免費獲取StockNews.com關於Becton、Dickinson和(BDX)的研究報告
  • 市場回顧周-1/30-2/3
  • 細價股值得嗎?你應該投資細價股嗎?
  • Zimmer Biomet盈利節節攀升,增長可能被計入價格
  • 人工智能軟件製造商EPAM號稱科技板塊漲幅最大
  • 福特股票在盈利大幅下滑後繼續前進

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.

接受Becton Dickinson和Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Becton Dickinson和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論